Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy a single institution experience

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 2, 2011, Pages 135-139

  Hammad, Nazik ^a   Heilbrun, Lance K ^a   Gupta, Sachin ^a   Tageja, Nishant ^b   Philip, Philip A ^a   Shields, Anthony F ^a   Smith, Daryn ^a   El Rayes, Bassel F ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MITOMYCIN;

ADULT; ANEMIA; ANUS CARCINOMA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AFRICAN AMERICANS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICHIGAN; MIDDLE AGED; MITOMYCIN; PREVALENCE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79955948103     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181dbb710     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281-288. (Pubitemid 38890830)
3. Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-deflning cancers in people with HIV infection before and after AIDS diagnosis. Aids. 2002;16:1155-1161. (Pubitemid 34533854)
4. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Deflc Syndr. 2004;37:1563-1565. (Pubitemid 39658192)
5. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeflciency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432. (Pubitemid 40528605)
6. Palefsky J. Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep. 2008;5:78-85. (Pubitemid 351656421)
7. Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354-356.
8. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the deflnitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527-2539. (Pubitemid 26300120)
9. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040-2049. (Pubitemid 27209535)
10. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914-1921. (Pubitemid 351574921)
11. Chiao EY, Giordano TP, Richardson P, et al. Human immunodeflciency virus-associated squamous cell cancer of the anus: epidemiology and out-comes in the highly active antiretroviral therapy era. J Clin Oncol. 2008;26:474-479. (Pubitemid 351171702)
12. Holland JM, Swift PS. Tolerance of patients with human immunodeflciency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology. 1994;193:251-254. (Pubitemid 24298031)
13. Oehler-Janne C, Huguet F, Provencher S, et al. HIV-speciflc differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26:2550-2557.
14. Vatra B, Sobhani I, Aparicio T, et al. Anal canal squamous-cell carcinomas in HIV positive patients: clinical features, treatments and prognosis [Article in French]. Gastroenterol Clin Biol. 2002;26:150-156. (Pubitemid 34267134)
15. Place RJ, Gregorcyk SG, Huber PJ, et al. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum. 2001;44:506-512. (Pubitemid 32336424)
16. Lee E, Wang JW. Statistical Methods for Survival Data Analysis. 3rd ed. Hoboken, NJ: Wiley & Sons, Inc;2003:76-91.
17. Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2005;48:1176-1181. (Pubitemid 40897861)
18. Seo Y, Kinsella MT, Reynolds HL, et al. Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeflcient patients. Int J Radiat Oncol Biol Phys. 2009;75:143-149.
19. Allen-Mersh T, Hanna-Morris A, Goldstone S. Is chemoradiaiton the treatment of choice for anal squamous cell carcinoma developing in HIV-positive patients with access to HAART. In: ASCO Gastrointestinal Cancer Symposium. San Francisco, CA; 2004.